Brief: Fusen Pharmaceutical Sees Loss Attributable RMB30 Mln To RMB45 Mln
20/08/2024 15:00
Aug 20 (Reuters) - Fusen Pharmaceutical Co Ltd
1652.HK :
* SEES LOSS ATTRIBUTABLE RMB30 MILLION TO RMB45 MILLION FOR
SIX
MONTHS
* SEES DECREASE IN REVENUE FOR SIX MONTHS
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA